NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
Last trade$0.7883
Day change-$0.0748 (-8.67%)
Day range$0.778 – $0.937
Volume36,938
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NCNA.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NCNA, quarterly periods
Line item
Q3 FY2024 Sep 30, 2024
Revenue
$0
Cost of revenue
$0
Gross profit
$0
Selling, general and administrative
$6.9M
Research and development
$26.25M
Total operating expenses
$33.15M
Operating income
-$33.15M
Interest expense
-$1K
Income before taxes
-$30.48M
Income taxes
$0
Net income
-$30.48M
Net income attributable to common shareholders
-$30.48M
EBITDA
-$31.56M
Basic earnings per share
-$5.44
Diluted earnings per share
-$5.44
Recent news
Company coverage with links to the original publishers.
NuCana plc announced the appointment of Theresa Bruce as Chief Operating Officer effective January 1, 2026. Bruce brings over 25 years of experience in oncology R&D and clinical operations. The appointment comes as NuCana plans to advance its pipeline with anticipated data readouts in 2026 for NUC-7738 and further characterization of NUC-3373, with cash runway extending into 2029.
NuCana presented clinical data at ESMO Immuno-Oncology Congress demonstrating promising results for NUC-7738 in treating PD-1 inhibitor-resistant metastatic melanoma, with two partial responses and seven cases of stable disease.
NuCana received a patent from China's National Intellectual Property Administration for NUC-7738, a novel anti-cancer agent currently in Phase 1/2 clinical trials, strengthening its global intellectual property strategy.
NuCana will present research on NUC-7738, a novel anti-cancer agent, at the ESMO Congress 2025 in Berlin, highlighting potential synergies between the drug and PD-1 inhibition in renal cell cancer.
NuCana reported a net loss of £7.0 million for Q2 2024 and had £11.6 million in cash as of June 30, 2024. The company is advancing its clinical programs, including NUC-3373 and NUC-7738, and expects to announce data readouts in the second half of 2024.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.